AstraZeneca Reports Results of Imfinzi (durvalumab) in P-III CASPIAN Study for 1L Extensive-Stage Small Cell Lung Cancer

 AstraZeneca Reports Results of Imfinzi (durvalumab) in P-III CASPIAN Study for 1L Extensive-Stage Small Cell Lung Cancer

AstraZeneca Reports Results of Imfinzi (durvalumab) in P-III CASPIAN Study for 1L Extensive-Stage Small Cell Lung Cancer

Shots:

  • The P-III CASPIAN study involves assessing of Imfinzi + etoposide + cisplatin/carboplatin or Imfinzi + tremelimumab + CT vs CT as monothx. as a 1L treatment for patients with extensive-stage SCLC across 22 countries including the US & EU
  • The P-III CASPIAN study resulted in meeting its 1EPs i.e, improvement in overall survival in SCLC patients. The safety & tolerability of combination therapy is consistent with the known safety profile
  • Imfinzi is a mAb targeting PD-L1, act by blocking the interaction of PD-L1 with PD-1 and CD80 and is an approved therapy in 45+ countries including the US, EU & Japan based on P-III PACIFIC study for unresectable, Stage III NSCLC

Click here to read full press release/ article | Ref: AstraZeneca | Image: The Guardian

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post